Products The first agent in the GLP-1 receptor agonist group to be approved was exenatide (Byetta) in the United States in 2005 and in many countries and the EU in 2006. In the meantime, several other drugs have been registered (see below). These drugs are also known as incretin mimetics. They are commercially available as … GLP-1 Receptor Agonists
Symptoms The possible acute symptoms of type 2 diabetes include: Thirst (polydipsia) and hunger (polyphagia). Increased urination (polyuria). Visual disturbances Weight loss Fatigue, exhaustion, declining performance. Poor wound healing, infectious diseases. Skin lesions, itching Acute complications: Hyperacidity (ketoacidosis), hyperosmolar hyperglycemic syndrome. Untreated diabetes is far from harmless and can lead in the longer term to … Diabetes Mellitus Type 2: Causes and Treatment
Effects Antiadiposita differ in their effects. They inhibit appetite or increase satiety, reduce the absorption of food components in the intestine or promote their utilization, increase energy metabolism and degrading metabolic processes. The ideal slimming agent would enable rapid, high and stable weight loss and at the same time be very well tolerated and applicable … Slimming Products
Products Liraglutide was approved in many countries in 2009 as a solution for injection in a prefilled pen (Victoza). In 2014, a fixed-dose combination with insulin degludec was released (Xultophy); see IDegLira. In 2016, Saxenda was registered for the treatment of overweight and obesity. Its related successor, semaglutide, unlike liraglutide, only needs to be injected … Liraglutide
Products Gliptins are commercially available in the form of film-coated tablets. Sitagliptin (Januvia) was the first representative to be approved in the United States in 2006. Today, various active ingredients and combination products are commercially available (see below). They are also called dipeptidyl peptidase-4 inhibitors. Structure and properties Some gliptins have a proline-like structure because … Gliptine
Products Insulin degludec is commercially available as a solution for injection (Tresiba). It is also combined fixed with insulin aspart (Ryzodeg, see under IDegAsp). It was newly approved in many countries in March 2013. In 2014, a fixed combination with liraglutide was registered (Xultophy); see under IDegLira. Structure and properties Insulin degludec has essentially the … Insulin Degludec
Active ingredients Insulins substitute for endogenous insulin: Human insulin Insulin analogues Biguanides reduce hepatic glucose formation: Metformin (Glucophage, generic). Sulfonylureas promote insulin secretion from beta cells: Glibenclamide (Daonil, generic). Glibornuride (Glutril, off label). Gliclazide (Diamicron, generic). Glimepiride (Amaryl, generics) Glinides promote insulin secretion from beta cells: Repaglinide (NovoNorm, generic). Nateglinide (Starlix) Glitazones decrease peripheral insulin … Antidiabetics
Products Human albumin is commercially available as an infusion solution for intravenous use. Structure and properties Human albumin is a monomeric protein with a heart-shaped structure that can be extracted from human plasma for the production of drugs. In the body, it is produced by the liver. The mature protein consists of 585 amino acids, … Albumin: Protein in the Blood
Definition Drugs today usually contain a defined active pharmaceutical ingredient. However, numerous drugs with two or more active substances also exist. These are called combination drugs or fixed combinations. For example, Aspirin C contains both acetylsalicylic acid and vitamin C. Many blood pressure medications are combination preparations, for example perindopril + indapamide or candesartan + … Combination Products
Symptoms Obesity manifests itself in an excessive amount of fatty tissue in the body. It represents a health, aesthetic, and psychosocial problem. Obesity is a risk factor for numerous diseases such as metabolic syndrome, type 2 diabetes mellitus, hypertension, dyslipidemia, cardiovascular disease, cancer, hormonal disorders, fatty liver, and osteoarthritis. Causes Obesity is primarily a disease … Overweight: How To Lose Weight
Products Semaglutide was approved in the US and EU in 2017 and in many countries in 2018 as a solution for injection (Ozempic). The agent is structurally and pharmacologically related to liraglutide (Victoza), which, unlike semaglutide, is injected once daily (both Novo Nordisk). In 2019, tablets containing semaglutide were approved for the first time in … Semaglutide
Background Medicines are usually stored at room temperature between 15 to 25 °C (sometimes up to 30 °C). However, for relatively many drugs, storage in the refrigerator at a temperature between 2 to 8 °C is mandatory. Why? At a low temperature, the molecular movement and reactivity of the compounds is reduced, germ growth is … Store Cool
